BR112022022719A2 - Vacinas para papilomatose respiratória recorrente e métodos de usar a mesma - Google Patents
Vacinas para papilomatose respiratória recorrente e métodos de usar a mesmaInfo
- Publication number
- BR112022022719A2 BR112022022719A2 BR112022022719A BR112022022719A BR112022022719A2 BR 112022022719 A2 BR112022022719 A2 BR 112022022719A2 BR 112022022719 A BR112022022719 A BR 112022022719A BR 112022022719 A BR112022022719 A BR 112022022719A BR 112022022719 A2 BR112022022719 A2 BR 112022022719A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- vaccines
- recurrent respiratory
- respiratory papillomatosis
- inducing
- Prior art date
Links
- 208000001307 recurrent respiratory papillomatosis Diseases 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 241000701806 Human papillomavirus Species 0.000 abstract 3
- 230000028993 immune response Effects 0.000 abstract 2
- 230000001939 inductive effect Effects 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 229940021995 DNA vaccine Drugs 0.000 abstract 1
- 206010038707 Respiratory papilloma Diseases 0.000 abstract 1
- 108010008038 Synthetic Vaccines Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 229940124590 live attenuated vaccine Drugs 0.000 abstract 1
- 229940023012 live-attenuated vaccine Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 abstract 1
- 229940124551 recombinant vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55538—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20071—Demonstrated in vivo effect
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063024912P | 2020-05-14 | 2020-05-14 | |
| PCT/US2021/032545 WO2021231925A1 (en) | 2020-05-14 | 2021-05-14 | Vaccines for recurrent respiratory papillomatosis and methods of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022022719A2 true BR112022022719A2 (pt) | 2023-02-14 |
Family
ID=78513438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022022719A BR112022022719A2 (pt) | 2020-05-14 | 2021-05-14 | Vacinas para papilomatose respiratória recorrente e métodos de usar a mesma |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11744885B2 (https=) |
| EP (1) | EP4149536A4 (https=) |
| JP (2) | JP7765407B2 (https=) |
| KR (1) | KR20230011335A (https=) |
| CN (1) | CN115803051A (https=) |
| AU (2) | AU2021271860B2 (https=) |
| BR (1) | BR112022022719A2 (https=) |
| CA (1) | CA3177949A1 (https=) |
| CO (1) | CO2022017989A2 (https=) |
| IL (1) | IL297903A (https=) |
| MX (1) | MX2022014248A (https=) |
| PE (1) | PE20230349A1 (https=) |
| PH (1) | PH12022553102A1 (https=) |
| SA (1) | SA522441314B1 (https=) |
| WO (1) | WO2021231925A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022022719A2 (pt) | 2020-05-14 | 2023-02-14 | Inovio Pharmaceuticals Inc | Vacinas para papilomatose respiratória recorrente e métodos de usar a mesma |
| US11409951B1 (en) * | 2021-09-24 | 2022-08-09 | International Business Machines Corporation | Facilitating annotation of document elements |
| CN114106207B (zh) * | 2022-01-24 | 2022-04-26 | 诺未科技（北京）有限公司 | Ccl5的用途 |
| US20240123052A1 (en) * | 2022-10-13 | 2024-04-18 | Inovio Pharmaceuticals, Inc. | Vaccines For Recurrent Respiratory Papillomatosis And Methods of Using the Same |
| CN121752584A (zh) * | 2023-05-22 | 2026-03-27 | 普瑞赛格恩公司 | 用于治疗复发性呼吸道乳头状瘤病的新型腺病毒疫苗疗法 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3805783A (en) | 1971-02-12 | 1974-04-23 | A Ismach | Hand powered hypodermic jet injector gun |
| US4342310A (en) | 1980-07-08 | 1982-08-03 | Istvan Lindmayer | Hydro-pneumatic jet injector |
| US4447223A (en) | 1982-04-16 | 1984-05-08 | Cct Associates | Medicament implant applicator |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5545130A (en) | 1992-04-08 | 1996-08-13 | Genetronics, Inc. | Flow through electroporation method |
| US5702359A (en) | 1995-06-06 | 1997-12-30 | Genetronics, Inc. | Needle electrodes for mediated delivery of drugs and genes |
| US5993434A (en) | 1993-04-01 | 1999-11-30 | Genetronics, Inc. | Method of treatment using electroporation mediated delivery of drugs and genes |
| US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
| US5505697A (en) | 1994-01-14 | 1996-04-09 | Mckinnon, Jr.; Charles N. | Electrically powered jet injector |
| US5869326A (en) | 1996-09-09 | 1999-02-09 | Genetronics, Inc. | Electroporation employing user-configured pulsing scheme |
| US6216034B1 (en) | 1997-08-01 | 2001-04-10 | Genetronics, Inc. | Method of programming an array of needle electrodes for electroporation therapy of tissue |
| US6055453A (en) | 1997-08-01 | 2000-04-25 | Genetronics, Inc. | Apparatus for addressing needle array electrodes for electroporation therapy |
| US6241701B1 (en) | 1997-08-01 | 2001-06-05 | Genetronics, Inc. | Apparatus for electroporation mediated delivery of drugs and genes |
| US6208893B1 (en) | 1998-01-27 | 2001-03-27 | Genetronics, Inc. | Electroporation apparatus with connective electrode template |
| US6009347A (en) | 1998-01-27 | 1999-12-28 | Genetronics, Inc. | Electroporation apparatus with connective electrode template |
| US6120493A (en) | 1998-01-27 | 2000-09-19 | Genetronics, Inc. | Method for the introduction of therapeutic agents utilizing an electroporation apparatus |
| JP2002520101A (ja) | 1998-07-13 | 2002-07-09 | ジェネトロニクス、インコーポレーテッド | 電気的に補助される化粧用薬剤の局部送達法および装置 |
| US6192270B1 (en) | 1998-08-14 | 2001-02-20 | Genetronics, Inc. | Apparatus and method for the delivery of drugs and genes into tissue |
| US6150148A (en) | 1998-10-21 | 2000-11-21 | Genetronics, Inc. | Electroporation apparatus for control of temperature during the process |
| US7171264B1 (en) | 1999-05-10 | 2007-01-30 | Genetronics, Inc. | Intradermal delivery of active agents by needle-free injection and electroporation |
| US6520950B1 (en) | 1999-05-10 | 2003-02-18 | Genetronics, Inc. | Method of electroporation-enhanced delivery of active agents |
| US7245963B2 (en) | 2002-03-07 | 2007-07-17 | Advisys, Inc. | Electrode assembly for constant-current electroporation and use |
| US7328064B2 (en) | 2002-07-04 | 2008-02-05 | Inovio As | Electroporation device and injection apparatus |
| MXPA05004860A (es) | 2002-11-04 | 2005-08-18 | Advisys Inc | Promotores musculares sinteticos con actividades que exceden las secuencias reguladoras de origen natural en las celulas cardiacas. |
| CA2653478A1 (en) * | 2009-01-23 | 2010-07-23 | Gregg Martin | Automated wash system for industrial vehicles |
| WO2014093894A2 (en) | 2012-12-13 | 2014-06-19 | The Trustees Of The University Of Pennsylvania | Dna antibody constructs and method of using same |
| AU2014248535B2 (en) | 2013-03-12 | 2017-03-30 | Inovio Pharmaceuticals, Inc. | Improved vaccines for human papilloma virus and methods for using the same |
| KR20150130284A (ko) | 2013-03-15 | 2015-11-23 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암 백신 및 이를 이용한 치료 방법 |
| MX2017007187A (es) | 2014-12-01 | 2018-01-30 | Univ Pennsylvania | Construcciones de anticuerpos de adn y metodo para utilizarlas. |
| AU2016274655B2 (en) | 2015-06-10 | 2021-06-17 | NeoTrail Therapeutics, Inc. | HPV vaccines |
| JP6920694B2 (ja) * | 2015-12-04 | 2021-08-18 | シアメン ユニバーシティＸｉａｍｅｎ Ｕｎｉｖｅｒｓｉｔｙ | ヒトパピローマウイルスタイプ１１のｌ１タンパク質の突然変異 |
| KR102222582B1 (ko) * | 2018-02-02 | 2021-03-04 | 주식회사 에스엘백시젠 | 신규 다가 hpv 백신 조성물 |
| US20230000969A1 (en) | 2019-10-24 | 2023-01-05 | Inovio Pharmaceuticals, Inc. | Improved vaccines for recurrent respiratory papillomatosis and methods for using the same |
| BR112022022719A2 (pt) | 2020-05-14 | 2023-02-14 | Inovio Pharmaceuticals Inc | Vacinas para papilomatose respiratória recorrente e métodos de usar a mesma |
| CA3223587A1 (en) | 2021-06-30 | 2023-01-05 | Paul Fisher | Side-port injection devices for use with electroporation, and related systems and methods |
-
2021
- 2021-05-14 BR BR112022022719A patent/BR112022022719A2/pt unknown
- 2021-05-14 WO PCT/US2021/032545 patent/WO2021231925A1/en not_active Ceased
- 2021-05-14 CN CN202180041036.2A patent/CN115803051A/zh active Pending
- 2021-05-14 PH PH1/2022/553102A patent/PH12022553102A1/en unknown
- 2021-05-14 CA CA3177949A patent/CA3177949A1/en active Pending
- 2021-05-14 MX MX2022014248A patent/MX2022014248A/es unknown
- 2021-05-14 AU AU2021271860A patent/AU2021271860B2/en active Active
- 2021-05-14 US US17/320,944 patent/US11744885B2/en active Active
- 2021-05-14 EP EP21804155.6A patent/EP4149536A4/en active Pending
- 2021-05-14 IL IL297903A patent/IL297903A/en unknown
- 2021-05-14 PE PE2022002641A patent/PE20230349A1/es unknown
- 2021-05-14 JP JP2022568868A patent/JP7765407B2/ja active Active
- 2021-05-14 KR KR1020227043183A patent/KR20230011335A/ko active Pending
-
2022
- 2022-11-14 SA SA522441314A patent/SA522441314B1/ar unknown
- 2022-12-12 CO CONC2022/0017989A patent/CO2022017989A2/es unknown
-
2023
- 2023-07-17 US US18/353,421 patent/US12478667B2/en active Active
-
2025
- 2025-07-10 JP JP2025116664A patent/JP2025158979A/ja active Pending
- 2025-08-26 AU AU2025220899A patent/AU2025220899A1/en active Pending
- 2025-10-29 US US19/373,135 patent/US20260053908A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20260053908A1 (en) | 2026-02-26 |
| US20210353736A1 (en) | 2021-11-18 |
| CO2022017989A2 (es) | 2022-12-20 |
| SA522441314B1 (ar) | 2024-08-05 |
| MX2022014248A (es) | 2022-12-02 |
| EP4149536A4 (en) | 2024-08-07 |
| CN115803051A (zh) | 2023-03-14 |
| US11744885B2 (en) | 2023-09-05 |
| US20230414744A1 (en) | 2023-12-28 |
| AU2021271860A1 (en) | 2022-12-15 |
| JP2025158979A (ja) | 2025-10-17 |
| WO2021231925A1 (en) | 2021-11-18 |
| US12478667B2 (en) | 2025-11-25 |
| PE20230349A1 (es) | 2023-03-02 |
| EP4149536A1 (en) | 2023-03-22 |
| JP7765407B2 (ja) | 2025-11-06 |
| IL297903A (en) | 2023-01-01 |
| KR20230011335A (ko) | 2023-01-20 |
| AU2025220899A1 (en) | 2025-09-18 |
| WO2021231925A8 (en) | 2022-03-24 |
| AU2021271860B2 (en) | 2025-06-05 |
| CA3177949A1 (en) | 2021-11-18 |
| PH12022553102A1 (en) | 2023-11-20 |
| JP2023525558A (ja) | 2023-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022022719A2 (pt) | Vacinas para papilomatose respiratória recorrente e métodos de usar a mesma | |
| BR112022014808A2 (pt) | Composições e métodos para vacinas para prevenir e tratar infecção pelo coronavírus-sars-cov-2 | |
| van Riet et al. | Mucosal IgA responses in influenza virus infections; thoughts for vaccine design | |
| BR112022015764A2 (pt) | Construções de ácido nucleico, vetores, vírus do sarampo, composições imunogênicas, processos para recuperar o vírus do sarampo, moléculas de ácido nucleico, polipeptídeos, proteínas recombinantes, usos in vitro de um antígeno, métodos para tratar ou prevenir uma infecção e para induzir uma resposta imune protetora | |
| Chaung et al. | Salmonella flagellin enhances mucosal immunity of avian influenza vaccine in chickens | |
| RU2653756C2 (ru) | Оптимизированные с помощью компьютера антигены с широким спектром реактивности для вирусов гриппа h3n2 | |
| BR112014015016A8 (pt) | Proteína homodimérica de duas cadeias de aminoácidos idênticas, cadeia de aminoácido, molécula de ácido nucléico, composição farmacêutica, célula hospedeira, método de preparação de uma proteína homodimérica, método para preparação de uma vacina, vacina e método de tratamento ou prevenção | |
| CN106995488A (zh) | 计算优化的宽反应性的h1n1流感抗原 | |
| BR112022016992A2 (pt) | Vacina com base em poxvírus recombinante contra ví-rus sars-cov-2 | |
| BR112015002131A2 (pt) | vacina de vírus sincicial respiratório (rsv) de vírus vaccínia ancara modificado recombinante | |
| BR112018076234A2 (pt) | vacina contra o vírus da bronquite infecciosa | |
| BRPI1007721B1 (pt) | composição de vacina para uso na indução de uma resposta imunológica contra um rotavírus em um indivíduo, cepa de rotavírus isolado de cdc-9 e cepa de rotavírus isolado de cdc-66 | |
| BR112018075420A2 (pt) | melhoramento da imunogenicidade de petídeo l2 | |
| BR112022011885A2 (pt) | Molécula de ácido nucleico, composição imunogênica, peptídeo, e, métodos para induzir uma resposta imune e para tratar ou prevenir uma patologia | |
| MX2015011487A (es) | Proteinas de consenso para el virus de la enfermedad de la fiebre aftosa (fmdv), secuencias de codificacion para estas y vacunas elaboradas a partir de estas. | |
| CO2023005978A2 (es) | Hvt recombinante y usos de este | |
| Gan et al. | Enhancing immunogenicity and protective efficacy of inactivated avian influenza H9N2vaccine with recombinant chicken IFN-α in chicken | |
| MX2023007228A (es) | Constructo de arn. | |
| BR112023021654A2 (pt) | Vacina contra vírus | |
| Yamazaki et al. | Inflammasomes in antiviral immunity: clues for influenza vaccine development | |
| Yang et al. | Protection against influenza H7N9 virus challenge with a recombinant NP–M1–HSP60 protein vaccine construct in BALB/c mice | |
| KR20150089005A (ko) | H1n1에 대한 계산적으로 최적화되고 넓은 반응성의 항원 | |
| BR112013013016A2 (pt) | modulação de imunogenicidade de antígeno pela eliminação de epítopos reconhecidos pelas células nkt14 | |
| AR122857A1 (es) | Ácido nucleico y secuencias de aminoácidos de adenovirus de gorila, vectores que los contienen, y usos de los mismos | |
| BR112022007615A2 (pt) | Método para tratar ou prevenir papilomatose respiratória recorrente, e, sequência de nucleotídeo |